Conference
A Phase II study of Sorafenib (BAY 43-9006) in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) and nasopharyngeal cancer (NPC)
Authors
Chen E; Winquist E; Agulnik M; Chin S; Pond G; Cheiken R; Francis P; Petrenciuc O; Siu L
Volume
3
Pagination
pp. 297-297
Publisher
PERGAMON-ELSEVIER SCIENCE LTD
Publication Date
October 1, 2005
Conference proceedings
EJC SUPPLEMENTS
Issue
2
ISSN
1359-6349